Table 2.

Histoclinical characteristics of all included patients with eosinophilic gastritis and or duodentitis

Characteristics	All included patients with eosinophilic gastritis at baseline (n = 5)	All included patients with eosinophilic gastritis on dupilumab (n = 5)	All included patients with eosinophilic duodenitis at baseline (n = 9)	All included patients with eosinophilic duodenitis on dupilumab (n = 9)
Peak gastric eos/hpf, median (min–max, Q1–Q3)	111 (32–150, 50–125)
Peak duodenal eos/hpf, median (min–max, Q1–Q3)			38 (30–139, 36–45)
Symptoms, n (%)
Dysphagia	4 (80)	0 (0)	8 (88.9)	2 (22.2)
Abdominal pain	4 (80)	2 (40)	8 (88.9)	4 (44.4)
Bloating/gas	2 (40)	2 (40)	2 (22.2)	2 (22.2)
Diarrhea	3 (60)	3 (60)	3 (33.3)	2 (22.2)
Constipation	2 (40)	2 (40)	3 (33.3)	1 (11.1)
Nausea/vomiting	4 (80)	2 (40)	6 (66.7)	1 (11.1)
Heartburn	5 (100)	2 (40)	7 (77.8)	2 (22.2)
Asymptomatic	0 (0)	2 (40)	0 (0)	3 (33.3)